COVID-19 outcomes and vaccination in people with relapsing multiple sclerosis treated with ofatumumab

Authors

Anne H Cross, Washington University School of Medicine in St. Louis
et al.

Journal

Neurology and Therapy

Publication Date

6-1-2022

Volume

11

Issue

2

First Page

741

Last Page

758

Document Type

Open Access Publication

DOI

10.1007/s40120-022-00341-z

Rights and Permissions

Cross, A.H., Delgado, S., Habek, M. et al. COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab. Neurol Ther 11, 741–758 (2022). https://doi.org/10.1007/s40120-022-00341-z This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Recommended Citation

Cross, Anne H and et al., "COVID-19 outcomes and vaccination in people with relapsing multiple sclerosis treated with ofatumumab." Neurology and Therapy. 11, 2. 741 - 758. (2022).
https://digitalcommons.wustl.edu/oa_4/444